

# New Reimbursement Policy on Costly Treatments for Rehabilitation Care in France: Estimated Impact in a University Hospital.

Legoupil T<sup>1</sup>, Tano M<sup>1,2,3</sup>, Siorat V<sup>1</sup>, Ribault M<sup>1</sup>, Parent de Curzon O<sup>1</sup>, Degrasat-Théas A<sup>1,2,3</sup>, Paubel P<sup>1,2,3</sup>


<sup>1</sup> General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France

<sup>2</sup> Health Law Institute, INSERM UMR S 1145, Paris Cité University, Paris, France

<sup>3</sup> Faculty of Pharmacy, Paris Cité University, Paris, France

## Introduction

Rehabilitation care (RC) funding in France is under reforming. A reimbursement policy of costly treatments will be introduced in 2023, similarly to acute care (AC) :



## Method



## Results

**RC (2021)** 21k full hospitalisation stays (554k AC full hospitalisation stays) 4k beds available (21% of AP-HP) 59% of beds in geriatric units

Fig. 1. Top 5 by cost of consumption of reimbursed molecules from AC list by ATC class, of RC units of AP-HP in 2021





Fig. 2. Top 5 by cost of consumption of reimbursed molecules from RC list, by ATC class, of RC units of AP-HP in 2021



Expenses are concentrated on few references

**LA**  
€ 1.5M, 3k units


= € 4.8M

0.4% of total drug cost of AP-HP (>1,1Md€)

54% of RC's total drug cost

**LR**  
€ 3.3M, 312k units

## Conclusion



The addition of a specific RC list better encompasses chronic treatments and broadens the access to costly molecules.



€ 3.3M secured, which represents 37% of the total budget for medicines in RC.



National fixed reimbursement rates will be published in 2023.